
Global R&D Pipeline
My Favorite
Hot Targets:
ACKR3
Back
Total number of drugs
19
Phase II and later clinical stages
5.3%
Involving companies
22
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TC-14012 | TC-14012 | Synthetic peptide | Neoplasms Immune System Diseases Infectious Diseases Respiratory Diseases Urogenital Diseases | atypical chemokine receptor 3 agonists C-X-C motif chemokine receptor 4 antagonists | Kyoto University | Peking UniversityUniversity of MontréalKyoto University | Preclinical | Preclinical | TC-14012 | detail > | |||||||||||
| CCX-650 | CCX-650 | Small molecule drug | Other Diseases | atypical chemokine receptor 3 inhibitors | ChemoCentryx, Inc. | Discovery | CCX-650 | detail > | |||||||||||||
| WO2026051808 | WO2026051808 | Small molecule drug | Digestive System Disorders Respiratory Diseases Urogenital Diseases Other Diseases | atypical chemokine receptor 3 agonists | Sichuan University | Sichuan University | Discovery | WO2026051808 | detail > | ||||||||||||
| WO2025196057 | WO2025196057 | Small molecule drug | Neoplasms Nervous System Diseases Cardiovascular Diseases Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Urogenital Diseases Other Diseases | atypical chemokine receptor 3 modulators | Luxembourg Institute of Health | Luxembourg Institute of Health | Discovery | WO2025196057 | detail > | ||||||||||||
| WO2023166190 | WO2023166190 | Small molecule drug | Neoplasms Immune System Diseases Nervous System Diseases Other Diseases | atypical chemokine receptor 3 modulators | InterAx Biotech AG | InterAx Biotech AG | Discovery | WO2023166190 | detail > | ||||||||||||
| CN117143821 | CN117143821 | Mesenchymal stem cell therapy | Respiratory Diseases Other Diseases | The 309th Hospital of Chinese Peoples Liberation Army | The 309th Hospital of Chinese Peoples Liberation Army | Discovery | CN117143821 | detail > | |||||||||||||
| ACKR3 agonists(Eberhard Karls Universität Tübingen) | ACKR3 agonists(Eberhard Karls Universität Tübingen) | Small molecule drug | Cardiovascular Diseases | atypical chemokine receptor 3 agonists | Eberhard Karls Universität Tübingen | Eberhard Karls Universität Tübingen | Discovery | ACKR3 agonists(Eberhard Karls Universität Tübingen) | detail > | ||||||||||||
| VUN-701 | VUN-701 | Nanobody | atypical chemokine receptor 3 inhibitors | Medical College of Wisconsin | Medical College of Wisconsin | Preclinical | VUN-701 | detail > | |||||||||||||
| VUF11207 | VUF11207 | Small molecule drug Liposomal Drug | Neoplasms Nervous System Diseases Other Diseases | atypical chemokine receptor 3 agonists | National Health Research Institutes | National Health Research Institutes | Preclinical | VUF11207 | detail > | ||||||||||||
| VUF-15485 | VUF-15485 | Chemical drugs | Neoplasms | atypical chemokine receptor 3 agonists | Vrije Universiteit Amsterdam | Vrije Universiteit Amsterdam | Preclinical | VUF-15485 | detail > |
Total 19 data
1
2


